Quality e-Newsletter
Intelligence Unit Special Reports Special Events Subscribe Sponsored Departments Follow Us

Twitter Facebook LinkedIn RSS

Fallout from back surgery product case prompting reforms

Journal Sentinel, December 29, 2011
Even before it went on the market in 2002, doctors were talking about how the back surgery product known as bone morphogenetic protein-2 would revolutionize medicine. It did - but in ways no one imagined. Instead of offering 100% success in fusing ailing spines with virtually no complications, BMP-2 became a biotech breakthrough associated with skepticism and scandal, epitomizing questions over whether corporate-funded research carried out by financially conflicted doctors can be trusted.